- Home
- PLX vs FATE Comparison
PLX vs FATE Comparison
Compare PLX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- FATE
- Stock Information
- Founded
- PLX 1993
- FATE 2007
- Country
- PLX United States
- FATE United States
- Employees
- PLX N/A
- FATE N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLX Health Care
- FATE Health Care
- Exchange
- PLX Nasdaq
- FATE Nasdaq
- Market Cap
- PLX 160.2M
- FATE 133.0M
- IPO Year
- PLX 1998
- FATE 2013
- Fundamental
- Price
- PLX $1.55
- FATE $1.21
- Analyst Decision
- PLX Strong Buy
- FATE Hold
- Analyst Count
- PLX 1
- FATE 8
- Target Price
- PLX $15.00
- FATE $4.14
- AVG Volume (30 Days)
- PLX 1.4M
- FATE 1.8M
- Earning Date
- PLX 05-09-2025
- FATE 05-13-2025
- Dividend Yield
- PLX N/A
- FATE N/A
- EPS Growth
- PLX N/A
- FATE N/A
- EPS
- PLX 0.05
- FATE N/A
- Revenue
- PLX $59,764,000.00
- FATE $13,335,000.00
- Revenue This Year
- PLX $65.02
- FATE N/A
- Revenue Next Year
- PLX $57.34
- FATE N/A
- P/E Ratio
- PLX $32.18
- FATE N/A
- Revenue Growth
- PLX 0.18
- FATE 105.85
- 52 Week Low
- PLX $0.82
- FATE $0.66
- 52 Week High
- PLX $3.10
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- FATE 53.44
- Support Level
- PLX $1.54
- FATE $1.12
- Resistance Level
- PLX $1.79
- FATE $1.38
- Average True Range (ATR)
- PLX 0.11
- FATE 0.12
- MACD
- PLX -0.02
- FATE 0.01
- Stochastic Oscillator
- PLX 27.27
- FATE 62.22
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.